Safety, Tolerability, and Pharmacokinetics of Crenezumab in Patients with Mild-to-Moderate Alzheimer’s Disease Treated with Escalating Doses for up to 133 Weeks

Pharmacokinetics and pharmacodynamic effect of crenezumab on plasma and cerebrospinal fluid beta-amyloid in patients with mild-to-moderate Alzheimer’s disease

(2020) Kenta Yoshida et al.   Alzheimers Research & Therapy

Characterization of the selective in vitro and in vivo binding properties of crenezumab to oligomeric Aβ

(2019) William J. Meilandt et al.   Alzheimers Research & Therapy

ABBY

(2018) Jeffrey L. Cummings et al.   NEUROLOGY

Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer’s disease (BLAZE)

(2018) Stephen Salloway et al.   Alzheimers Research & Therapy

Burden and risk factors of ambulatory or hospitalized CAP: A population based cohort study

(2016) Martin Kolditz et al.   RESPIRATORY MEDICINE

Structure of Crenezumab Complex with Aβ Shows Loss of β-Hairpin

(2016) Mark Ultsch et al.   Scientific Reports

Alzheimer's disease

(2015) Colin L. Masters et al.   Nature Reviews Disease Primers

Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014

(2014) L. S. Schneider et al.   JOURNAL OF INTERNAL MEDICINE

An MRI Rating Scale for Amyloid-Related Imaging Abnormalities with Edema or Effusion

(2013) F. Barkhof et al.   AMERICAN JOURNAL OF NEURORADIOLOGY

Neurotoxicity of Amyloid  -Protein: Synaptic and Network Dysfunction

(2013) L. Mucke et al.   Cold Spring Harbor Perspectives in Medicine

An Effector-Reduced Anti- -Amyloid (A ) Antibody with Unique A  Binding Properties Promotes Neuroprotection and Glial Engulfment of A 

(2012) O. Adolfsson et al.   JOURNAL OF NEUROSCIENCE

Beneficial effect of human anti-amyloid-β active immunization on neurite morphology and tau pathology

(2010) Alberto Serrano-Pozo et al.   BRAIN

Amyloid-β–induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks

(2010) Jorge J Palop et al.   NATURE NEUROSCIENCE

Oligomeric amyloid   associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques

(2009) R. M. Koffie et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA